Showing 1741-1750 of 2038 results for "".
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- Regeneron Wins Patent Case to Extend Eylea Protectionhttps://modernod.com/news/regeneron-wins-patent-case-to-extend-eylea-protection/2482035/A West Virginia judge ruled that Viatris' proposed biosimilar violates a Regeneron patent that covers ophthalmic formulations of Eylea, according to news reports. The patent is expected to expire in June 2027.
- Lupin Receives FDA Approval for Generic Loteprednol Etabonate Ophthalmic Suspensionhttps://modernod.com/news/lupin-receives-fda-approval-for-generic-loteprednol-etabonate-ophthalmic-suspension/2482032/Mumbai, India-based Lupin announced that it has received approval from the FDA for its abbreviated new drug application for Loteprednol etabonate ophthalmic suspension, 0.2%. The formuation is a generic equivalent to the reference listed drug Alrex Ophthalmic Suspension, 0.2%
- Johnson & Johnson Buys Gene Therapy Eye Portfolio from MeiraGTxhttps://modernod.com/news/johnson-johnson-buys-gene-therapy-for-x-linked-retinitis-pigmentosa-from-meiragtx/2482024/Johnson & Johnson, through its Janssen Pharmaceuticals division, has acquired the rights to investigational gene therapy botaretigene sparoparvovec (bota-vec; formerly AAV-RPGR) for patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) from MeiraGTx.<
- NEI Study Shows How Genes in Retina Get Regulated During Developmenthttps://modernod.com/news/nei-study-shows-how-genes-in-retina-get-regulated-during-development/2482012/Using models of a retina grown in the lab, researchers at the National Eye Institute say they have mapped the 3D organization of genetic material of key developmental stages of human retinal formation. The findings lay a foundation for understanding clinical traits in many eye diseases, and
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev
- Nanoscope Therapeutics Announces Presentations at Upcoming Conferenceshttps://modernod.com/news/nanoscope-therapeutics-announces-presentations-at-upcoming-conferences/2481862/Nanoscope Therapeutics, which is developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- Study Finds Role of Biosynthetic Fatty Acid Pathway Insufficiencies in Age-Related Macular Degenerationhttps://modernod.com/news/study-finds-role-of-biosynthetic-fatty-acid-pathway-insufficiencies-in-age-related-macular-degeneration/2481831/LSU Health Sciences Center announced the publication of findings that suggest that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential. The research was led by Nicolas Bazan,
- Business Executive Alex Gorsky Joins Neurotech’s Board as Lead Directorhttps://modernod.com/news/business-executive-alex-gorsky-joins-neurotechs-board-as-lead-director/2481827/Neurotech Pharmaceuticals announced that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Mr. Gorsky is the former Chairman and CEO of Johnson & Johnson. Under Mr. Gorsky’s leadership, Johnson & Johnson grew to become one of world’s larg